CANTOS, a canakinumab anti-inflammatory thrombosis outcome study, demonstrated that inhibiting IL-1 and IL-6 can reduce the rates of cardiovascular events, especially IL-6, which is directly related to the risk of the occurrence of atherosclerosis (Ridker et al., 2017; Ridker et al., 2018). This evidence concerns the gene IL6 and atherosclerosis.